Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6536-0.0513 (-7.28%)
At close: 04:00PM EST
0.6540 +0.00 (+0.06%)
After hours: 06:18PM EST
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma

    Graybug Vision Inc (NASDAQ: GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has bee

  • GlobeNewswire

    Graybug and CalciMedica Enter into Definitive Merger Agreement

    – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi

  • GlobeNewswire

    Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

    REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s

Advertisement
Advertisement